Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system

Bouget, J.; Balusson, Frédéric; Kerbrat, Sandrine; Roy, Pierre Marie; Viglino, Damien; Lacut, Karine; Pavageau, Laure; Oger, Emmanuel

doi:10.1007/s00228-022-03318-x

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is recommended for the treatment of DVT with or without PE, for extended treatment of venous thromboembolism and prevention of recurrences in adult patients with active cancer but also for VTE prophylaxis for both non-surgical immobilized patients (due to acute heart failure, acute respiratory failure, severe infections, active cancer, as well as exacerbation of rheumatic diseases) as well as in adult patients undergoing surgery, particularly orthopedic, general, or oncological surgery. It is also indicated for prevention of clotting in extracorporeal circuits during hemodialysis and hemofiltration in adults [ 6 , 7 ] and in our knowledge, tinzaparin is widely used in various European countries, especially for the management of cancer-associated thrombosis (CAT) [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses

Amerali

Politou

2022

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose Low molecular weight heparins (LMWHs) are a group of heterogenous moieties, long used in the prevention and treatment of thrombosis. They derive from heparin and since they are prepared by different methods of depolymerization, they differ in pharmacokinetic properties and anticoagulant profiles, and thus are not clinically interchangeable. Methods In this review we provide an overview of tinzaparin's main characteristics and uses. Results Tinzaparin which is produced by the enzymatic depolymerization of unfractionated heparin (UFH) can be used for the treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE); it has been also used in special populations such as elders, obese, pregnant women, and patients with renal impairment and/or cancer with favorable outcomes in both safety and efficacy, with a once daily dose regimen. Furthermore, LMWHs are extensively used in clinical practice for both thromboprophylaxis and thrombosis treatment of COVID-19 patients. Conclusion Tinzaparin features support the hypothesis for having a role in immunothrombosis treatment (i.e. in the context of cancer ,COVID-19), interfering not only with coagulation cascade but also exhibiting anti-inflammatory potency.

show abstract

Section: Introductionmentioning

confidence: 99%